

Zoono Group Limited

ABN: 73 006 645 754

Level 12
225 George Street
Sydney NSW 2000

T: +61 (2) 8042 8481

www.zoono.com



3 December 2018

ASX RELEASE

Zoono Files Legal Proceedings Against Stayzon

Global biotech company, Zoono Group Limited (ASX: ZNO) ('Zoono' or 'the Company'), advises that it has commenced legal proceedings against MCS Capital Partners Pty Limited and Stayzon Retail Ventures Pty Limited (together, 'Stayzon') for breach of the Deed of Settlement pursuant to which Zoono and Stayzon ended their supply agreement in March 2018.

Zoono believes Stayzon has engaged in, and continues to engage in, making false and misleading statements in the marketing and sale of Stayzon products. Proceedings have been filed in the Auckland High Court. Zoono will advise of the outcome of these proceedings in due course.

For further Information please contact:

Paul Hyslop
Managing Director/CEO
+64 21 659977
paul.hyslop@zoono.com

Media enquiries

Julia Maguire
The Capital Network
P: +61 419 815 386
julia@thecapitalnetwork.com.au

About Zoono:

Zoono is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com